Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (Nasdaq: ECOR) is a commercial-stage bioelectronic medicine and wellness company that regularly issues news on its non-invasive neuromodulation technologies, prescription therapies, and wellness and performance devices. This news feed aggregates company press releases, clinical study announcements, reimbursement developments, corporate updates, and other disclosures directly related to electroCore.
Readers can follow updates on electroCore’s prescription products, including gammaCore non-invasive vagus nerve stimulation (nVNS) and the Quell neurostimulator for chronic pain syndromes, as well as its handheld Truvaga and TAC-STIM devices for general wellness and human performance. News items have covered peer-reviewed studies on gammaCore in persistent post-concussion symptoms, controlled trials of TAC-STIM in active-duty Air Force trainees, and recognition of Truvaga Plus in consumer-focused awards.
The ECOR news stream also includes financial and corporate information such as quarterly results, revenue trends, private placements, participation in investor conferences, and changes to the board of directors and executive team. Regulatory and market access milestones, like reimbursement decisions for gammaCore Sapphire in Belgium, appear alongside product and clinical updates.
Investors, clinicians, and individuals interested in bioelectronic medicine can use this page to review electroCore’s historical and recent announcements in one place. For deeper analysis of any item, users can combine these news releases with the company’s SEC filings and other official documents accessible through related sections of the platform.
electroCore (NASDAQ: ECOR) has announced a partnership with former New York Jets linebacker Greg Buttle to promote Truvaga™ Plus, their next-generation vagus nerve stimulation (nVNS) device. The partnership aims to raise awareness about the device's benefits for sleep improvement and stress relief.
Truvaga is a portable wellness device that stimulates the vagus nerve in two-minute sessions, helping users achieve better sleep and relaxation without medication. The partnership includes radio spots and digital campaigns, leveraging Buttle's NFL experience and broadcasting background to showcase how Truvaga supports stress management and sleep quality.
electroCore (NASDAQ: ECOR), a bioelectronic medicine and wellness company, has appointed Elena Bonfiglioli to its Board of Directors, effective September 2, 2025. Bonfiglioli, who currently serves as Microsoft's Global Business Leader for Healthcare, Pharma Life Sciences, and International clinical applications' solutions, brings over two decades of healthcare sector experience.
Bonfiglioli, recognized as one of the top 50 AI Innovators by Intelligent Health, replaces Peter Cuneo on the board. She currently serves on the Drug Information Association Regional Advisory Council and holds board positions at several European and Middle Eastern startups. Her expertise spans AI transformation initiatives in healthcare, data utilization for research, and longevity sector innovations.
electroCore (NASDAQ:ECOR), a bioelectronic medicine and wellness company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The event will be held on September 9, 2025, at the Lotte New York Palace Hotel in New York.
The company's management team will be available for one-on-one meetings throughout the conference day. Interested investors can schedule meetings through their H.C. Wainwright sales representative or by contacting electroCore's Investor Relations directly.
electroCore (NASDAQ: ECOR), a bioelectronic medicine and wellness company, has appointed Kelly Benning as Senior Vice President of Truvaga, effective July 21, 2025. Benning brings nearly 30 years of leadership experience in digital health, AI technologies, and consumer wellness.
Benning's impressive background includes pioneering the first FDA-cleared blood pressure monitoring watch and holding executive positions at LiveMetric, IBM Watson Health, CipherHealth, and other healthcare companies. In her new role, she will lead electroCore's consumer wellness division, focusing on strategic partnerships and expanding access to consumer devices through the company's digital wellness platform, Truvaga.
[ "Appointment of experienced executive with nearly 30 years in digital health and AI technologies", "Strategic focus on expanding direct-to-consumer market access", "Addition of leader with proven track record in FDA-cleared medical device commercialization" ]electroCore (NASDAQ: ECOR) reported strong Q2 2025 financial results with record revenue of $7.4 million, representing a 20% year-over-year increase. The company's year-to-date revenue reached $14.1 million, up 22% compared to the first half of 2024.
Key financial metrics include gross profit of $6.4 million with an 87% margin, though operating expenses increased to $9.9 million. The company reported a GAAP net loss of $3.7 million ($0.44 per share). Cash position stood at $7.4 million as of June 30, 2025, supplemented by a recent $7.2 million term debt facility.
electroCore projects full-year 2025 revenue of approximately $30.0 million with expected net cash usage between $3.9-$4.4 million for the remainder of the year. The company successfully completed the NeuroMetrix acquisition ahead of schedule.
electroCore (Nasdaq: ECOR), a bioelectronic medicine and wellness company, has appointed James C. Theofilos to its Board of Directors, effective August 1, 2025.
Theofilos currently serves as Senior Finance Manager in Microsoft's Azure and AI division, leading finance for the AI Apps & Agents team. His experience includes roles as Finance Lead for Microsoft's Global Healthcare & Life Sciences Sales team and as Group Project Manager at VICI Properties. The Theofilos family has been an early investor and founding partner of electroCore, demonstrating long-term commitment to the company's vision in vagus nerve technology.
electroCore (NASDAQ: ECOR), a bioelectronic medicine and wellness company, has scheduled its Q2 2025 financial results announcement for Wednesday, August 6, 2025, after market close.
The company will host an interactive webinar at 4:30 PM EDT where management will review financial results and take questions from participants. Investors can join using the dial-in number (646) 931-3860, with Webinar ID 843 8084 9004 and Passcode 049555.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has announced its participation in two upcoming investor conferences in August 2025.
The company will attend the Needham 10th Annual Virtual MedTech and Diagnostics Conference on August 11-12, 2025, offering one-on-one meetings. Additionally, management will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on August 12 at 3:30 p.m. ET, also providing one-on-one meeting opportunities during the event.
electroCore (NASDAQ: ECOR) reported strong Q1 2025 financial results with net sales of $6.7 million, representing a 23% increase from Q1 2024. The company's core revenue excluding TAC-STIM grew by 29% year-over-year to $6.6 million. Key growth drivers included higher sales of prescription gammaCore™ in the VA market, international market expansion, and strong performance of Truvaga™ wellness products.
The company maintained a robust gross margin of 85%. However, operating expenses increased to $9.5 million, resulting in a GAAP net loss of $3.9 million ($0.47 per share). The quarter included $665,000 in seasonal and non-recurring expenses related to Form 10-K filing, severance, and the NeuroMetrix acquisition.
electroCore provided full-year 2025 guidance of approximately $30.0 million in total revenue and projects net cash usage of $3.8-4.3 million for the next three quarters. The company closed the quarter with $8.0 million in cash and equivalents.
electroCore (NASDAQ: ECOR) has completed its merger with NeuroMetrix (NASDAQ: NURO), acquiring the Quell® Fibromyalgia Solution platform. The acquisition positions electroCore as a leading player in non-invasive bioelectronic technologies, expanding its portfolio in chronic pain and wellness markets. Under the merger terms, NURO shareholders received $4.49 per share in cash plus one contingent value right (CVR) tied to future Quell business sales milestones and proceeds from DPNCheck business disposition.
The strategic acquisition is expected to leverage electroCore's established distribution channels, particularly within the VA Hospital System, to accelerate Quell Fibromyalgia solution adoption. Following the merger completion, NeuroMetrix became an indirect wholly-owned subsidiary of electroCore, with NURO shares being delisted from Nasdaq on May 2, 2025.
FAQ
What is the current stock price of Electrocore (ECOR)?
What is the market cap of Electrocore (ECOR)?
